EXPEDITION
Live / Registered — Registered (as of 11 Aug 2026)
What this means for you
Registered since 11 Aug 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 11 Aug 2032: the §8 declaration of use).
Record
- Serial number
- 98978174
- Registration number
- 8394632
- Mark type
- Word mark
- Filed
- 04 Oct 2024
- Published for opposition
- 16 Sept 2025
- Registered
- 11 Aug 2026
- Next maintenance filing
- §8 declaration of use, due by 11 Aug 2032 (grace period to 11 Feb 2033)
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule therapeutics, namely, therapeutic agents for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders; protein-based and small molecule pharmaceuticals for the treatment, prevention, mitigation, management, or diagnosis of cancer, and viral, bacterial, fungal, parasitic, prion-based, metabolic, endocrine, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, immune system-related, autoimmune, genetic, rare, hematological, musculoskeletal, rheumatological, renal, nutritional, otolaryngological, pediatric, developmental, age-related, and pain-related diseases and disorders
- Class 042 — Scientific and technological services: Scientific research, namely, research and analysis services for the design and characterization of chemical therapeutic products; research services in the fields of proteomic analysis; proteomic analysis for scientific and research purposes; medical and scientific research in the field of proteomics; research and development in the field of proteomics; medical research, namely, compiling data for research purposes in the field of proteomics
Owner
- EXPEDITION MEDICINES, INC., CAMBRIDGE, MA, US
- EXPEDITION MEDICINES, INC., CAMBRIDGE, MA, US
- EXPEDITION MEDICINES, INC., CAMBRIDGE, MA, US
- Flagship Labs 94, Inc., Cambridge, MA, US
Prosecution history
- 11 Aug 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 11 Aug 2026 — REGISTERED-PRINCIPAL REGISTER
- 21 Jul 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 21 Jul 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 16 Jul 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Jul 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Jul 2026 — ASSIGNED TO LIE
- 14 Jul 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Jun 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 10 Jun 2026 — NON-FINAL ACTION E-MAILED
- 10 Jun 2026 — SU - NON-FINAL ACTION - WRITTEN
- 27 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 May 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 11 Dec 2025 — USE AMENDMENT FILED
- 26 May 2026 — SOU EXTENSION 2 GRANTED